

INTRODUCTION .....	XIX
OBJECTIVES AND GOALS OF STUDY .....	XIX
CONTRIBUTION OF THE STUDY AND FOR WHOM .....	XIX
ZEROING IN ON VIABLE DRUG CANDIDATES .....	XX
STUDY SCOPE AND FORMAT .....	XX
METHODOLOGY .....	XX
INFORMATION SOURCES .....	XXI
AUTHOR'S CREDENTIALS .....	XXI
RELATED BCC WORK CREDENTIALS INCLUDING WORK BY OTHER AUTHORS .....	XXI
BCC ON-LINE SERVICES.....	XXII
 SUMMARY.....	 XXIII
<i>SUMMARY TABLE THE MARKET FOR GENOMICS-BASED TECHNOLOGIES         USED IN DRUG TARGET SCREENING, IDENTIFICATION, AND VALIDATION,         THROUGH 2007 (\$ MILLIONS)</i> .....	   XXIII
<i>SUMMARY FIGURE THE MARKET FOR GENOMICS-BASED TECHNOLOGIES         USED IN DRUG TARGET SCREENING, IDENTIFICATION, AND VALIDATION,         2001-2007 (\$ MILLIONS)</i> .....	   XXIV
 OVERVIEW .....	 1
A REVOLUTION IN POSSIBILITIES .....	1
GENOMICS—A BRIEF DEFINITION .....	1
THE CRITICAL NEED FOR DRUG TARGET VALIDATION.....	1
FROM DISCOVERY TO DELIVERY .....	2
WHERE HAVE ALL THE APPROVALS GONE? .....	2
THE DEFINITION OF A VALIDATED DRUG TARGET .....	3
MARKET INTRODUCTION OF GENOMICS-BASED DRUGS .....	4
CATEGORIES OF GENOMICS-BASED DRUGS.....	4
METHODS OF DISCOVERY FOR SMALL MOLECULE DRUGS .....	4
THE HUMAN GENOME PROJECT .....	5
HOW MANY GENES IN THE HUMAN GENOME? .....	5
Laboratory and Computer Predictions .....	6
OTHER OBJECTIVES OF THE HGP .....	6
THE SINGLE NUCLEOTIDE POLYMORPHISM (SNP) CONSORTIUM .....	 7
THE HUMAN GENOME CONSORTIUM.....	7
A LITTLE MICROBIOLOGY, PLEASE .....	8
REGULATORY, INTRON, AND EXON.....	8
mRNA Splicing .....	8
Alternative Splice Forms Vary.....	9
DEFINITIONS .....	9
GENOMICS .....	9
Amplification.....	10
Amplified Genes.....	10

Biochips.....	10
Bioinformatics.....	10
Biological Pathways.....	11
CLINICAL GENOMICS.....	11
Clone .....	11
Cloning Vector .....	12
COMBINATORIAL CHEMISTRY.....	12
COMPARATIVE GENOMICS .....	12
cDNA.....	12
COMPUTATIONAL CHEMISTRY.....	12
Conserved Sequence .....	13
DNA.....	13
DNA Microarray .....	13
DNA Sequence .....	14
DNA sequencing.....	14
DISEASE TARGETS.....	14
Disease Target Validation.....	14
DOMAIN.....	14
DRUG DISCOVERY.....	14
Drug Target .....	15
Embryonic Stem Cells .....	15
EXPRESSED SEQUENCE TAG (EST).....	15
Eukaryote.....	16
Exon .....	16
FUNCTIONAL GENOMICS.....	16
GENE EXPRESSION.....	17
Link Between a Gene and Disease .....	17
Gene Expression Pattern.....	17
Expression Variability.....	17
Shifts in Management and Diagnostics .....	18
Regulation of Gene Expression .....	18
Response Failure to Protection .....	19
Approaches to High-throughput Analysis of Gene Expression .....	19
<i>TABLE 1 HIGH-THROUGHPUT TECHNOLOGIES USED IN ANALYSIS OF GENE EXPRESSION LEVELS.....</i>	<i>19</i>
Research Applications of Gene Expression Studies .....	20
Gene Profiling .....	20
Expression Profiling .....	21
Biochemically Most Interesting .....	21
Technologies Used in Expression Profiling.....	21
High-throughput Technologies .....	22
Limitations of Expression Profiling.....	22
Positional Cloning.....	23
Locating the Exact Genetic Address .....	23

Pathway Profiling .....	23
Differential Display .....	24
Bead-Based Technologies .....	24
Gene Mapping .....	24
Gene Variations .....	25
Genome Mapping .....	25
Access to Study Populations .....	26
Single-Gene Defects .....	26
Normal Gene Shuffling.....	26
Gene Variants in Complex Diseases .....	27
Types of Mapping Studies .....	27
Linkage Studies.....	27
Disequilibrium Studies.....	28
Association Studies .....	28
The Quest for a High-Density Map .....	29
Gene Sequencing .....	29
Applications of DNA Sequence Variation .....	30
Polymorphism Discovery .....	30
GENETIC MARKERS.....	31
Genome .....	31
Genotype .....	31
Genotyping.....	31
Haplotype .....	32
High-Throughput.....	32
Highly Conserved Sequence.....	32
Homology .....	32
Hybridization.....	32
<i>In Vitro</i> .....	32
PCR .....	32
<i>In Vivo</i> .....	33
<i>In Silico</i> .....	33
INTRON.....	33
JUNK DNA.....	33
KARYOTYPE.....	33
Knockout .....	33
Lead (Drug) Candidate.....	33
Lead (Drug) Discovery.....	34
LINKAGE MAP.....	34
Mapping .....	34
Physical Map.....	34
MESSENGER RNA (mRNA) .....	34
Microarrays.....	34
MICROFLUIDICS.....	35
MODEL SYSTEMS .....	35

MUTATIONS.....	35
NUCLEOTIDES .....	35
Nucleic Acid .....	36
Oligo or Oligonucleotide .....	36
PHARMACOGENOMICS .....	36
PHENOTYPE .....	36
PCR .....	36
POLYMORPHISM .....	36
POSITIONAL CLONING.....	37
PROBE.....	37
Probe Array.....	37
PROTEIN FRAGMENT COMPLEMENTATION ASSAY (PCA).....	37
PROTEINS .....	37
Proteome .....	38
Proteomics .....	38
RECOMBINANT DNA TECHNOLOGY.....	38
RESTRICTION ENZYMES .....	38
Reverse Transcriptase.....	38
RNA.....	38
Ribosomes .....	39
Screening.....	39
SECRETED PROTEINS .....	39
SEQUENCING.....	39
SEQUENCE VARIABILITY .....	40
Correlating Variability in Gene Sequence with Disease .....	40
SNP .....	41
Using SNPs to Understand and Treat Disease .....	41
SNP Scoring.....	42
The Tools for SNP Genotyping.....	42
Hardware .....	42
Software .....	42
Reagents .....	43
DNA Microarrays.....	43
Mass Spectrometry .....	43
High-Efficiency Fluorescence Polarization (HEFP) .....	44
SMALL MOLECULE DRUGS.....	44
Structural Genomics.....	44
(Drug) Target Identification.....	44
(Drug) Target Screening.....	44
(Drug) Target Validation .....	45
TOXICOGENOMICS .....	45
Transcription .....	45
Transgenic.....	45
Translation.....	45

DRUG TARGET VALIDATION TECHNOLOGIES AND STRATEGIES .....	46
NO DIRECT LINK.....	46
TWO BEST APPROACHES.....	46
Focusing on Druggable Targets .....	47
THE EMERGING ROLE OF CHEMICAL GENETICS .....	47
PRIMARY TECHNOLOGIES USED IN GENOMICS-BASED DRUG	
TARGET VALIDATION .....	47
BIOINFORMATICS .....	48
LEADING COMPETITORS IN THE BIOINFORMATICS	
MARKET .....	49
Cutting-Edge Technology Products .....	50
Celera Genomics .....	51
Deltagen.....	51
Entelos .....	52
Saving Time and Expense with R&D .....	52
Genedata .....	53
Analyzing the Genomes .....	53
Gene Logic.....	53
BioExpress Module and ToxExpress Module .....	54
Incyte Genomics.....	54
A Many-faceted Portfolio .....	55
Lexicon Genetics .....	55
Myriad Genetics.....	55
THE MARKET FOR BIOINFORMATICS .....	56
Considering the Market .....	56
TABLE 2 THE MARKET FOR BIOINFORMATICS, THROUGH 2007 (\$ MILLIONS) .....	56
FIGURE 1 THE MARKET FOR BIOINFORMATICS, 2001-2007 (\$ MILLIONS).....	57
Fastest Growing Sector .....	57
COMPARATIVE/FUNCTIONAL GENOMICS.....	58
TABLE 3 THE MARKET FOR FUNCTIONAL GENOMICS, THROUGH 2007 (\$	
MILLIONS) .....	58
FIGURE 2 THE MARKET FOR FUNCTIONAL GENOMICS, 2001-2007 (\$ MILLIONS).....	59
THE DNA MICROARRAY MARKET.....	59
One Cost-Effective Experiment.....	60
The DNA Microarray as a Tool .....	60
A Quantum Leap for Genomics.....	61
Structure of the Industry .....	61
The Market for DNA Microarray-related Products.....	62
TABLE 4 THE MARKET FOR MICROARRAYS, ARRAYERS, SCANNERS AND	
MICROFLUIDICS, THROUGH 2007 (\$ MILLIONS).....	63
FIGURE 3 THE MARKET FOR MICROARRAYS, ARRAYERS, SCANNERS AND	
MICROFLUIDICS, 2001-2007 (\$ MILLIONS) .....	63
The Market for DNA Microarrays .....	63
TABLE 5 THE MARKET FOR MICROARRAYS, THROUGH 2007 (\$ MILLIONS) .....	64
FIGURE 4 THE MARKET FOR MICROARRAYS, 2001-2007 (\$ MILLIONS).....	64
TABLE 6 TYPES OF DNA MICROARRAYS PURCHASED BY END USERS, 2001-	
2007 (%).....	65

<i>FIGURE 5 TYPES OF DNA MICROARRAYS PURCHASED BY END USERS, 2001-2007 (%).....</i>	<i>65</i>
<i>TABLE 7 THE MARKET FOR PREFABRICATED DNA MICROARRAY BIOCHIPS: HIGH DENSITY, LOW DENSITY AND CUSTOM, THROUGH 2007 (\$ MILLIONS).....</i>	<i>66</i>
<i>FIGURE 6 THE MARKET FOR PREFABRICATED DNA MICROARRAY BIOCHIPS: HIGH DENSITY, LOW DENSITY AND CUSTOM, THROUGH 2007 (\$ MILLIONS).....</i>	<i>66</i>
Market Drivers .....	67
Available Products and Technologies .....	68
Creating One's Own DNA Arrays .....	69
High Density Microarrays .....	69
High Density Microarrays Will Always Have a Place .....	70
Market Growth.....	70
<i>TABLE 8 HIGH DENSITY MICROARRAY BIOCHIPS: SALES VOLUME AND UNIT PRICE, THROUGH 2007 .....</i>	<i>71</i>
Geographic Markets.....	71
Low Density Microarrays .....	71
Uses .....	72
Market Growth.....	72
<i>TABLE 9 LOW DENSITY MICROARRAYS: SALES VOLUME AND UNIT PRICE, THROUGH 2007 .....</i>	<i>73</i>
Geographic Markets.....	73
Leaders and Market Shares.....	73
Custom Microarrays .....	73
Reason for Purchasing Custom Arrays is Changing .....	74
Demand for Custom Arrays .....	74
The Cost of a Custom Microarray.....	74
Uses .....	74
Market Growth.....	75
Prices and Volumes.....	75
<i>TABLE 10 CUSTOM MICROARRAYS: VOLUME SALES AND UNIT PRICES, THROUGH 2007 .....</i>	<i>75</i>
Geographic Markets.....	75
Leaders and Market Shares.....	76
Strategies/Directions .....	76
Pricing of High-Density, Low-Density, and Custom Arrays.....	76
<i>TABLE 11 ESTIMATED AND PROJECTED PRICES FOR VARIOUS TYPES OF PREFABRICATED DNA MICROARRAYS, 2001-2007 (\$)</i> .....	<i>76</i>
In-House Made Arrays.....	77
<i>TABLE 12 THE MARKET FOR IN-HOUSE MADE DNA MICROARRAYS, THROUGH 2007 (\$ MILLIONS)</i> .....	<i>77</i>
New Technologies in DNA Microarrays .....	77
Tissue Microarrays (TMA).....	78
The Tissue Array Research Program (TARP) .....	78
Leading Competitors .....	79

	Affymetrix.....	79
	Custom Express via the Internet .....	80
	Motorola .....	80
	Nanogen .....	81
	Sequenom Biotherapeutics.....	81
	Finding the Most Efficient Technique .....	82
	Arrayers .....	82
	Inkjet-style Printing Technology .....	82
	The Market for Arrayers .....	83
TABLE 13	<i>THE MARKET FOR ARRAYERS, THROUGH 2007 (\$ MILLIONS)</i> .....	83
	Labeling and Detection .....	83
	Scanning and Image Analysis.....	84
	Obtaining a Statistically Valid Estimate of the Probe Cell's Intensity .....	84
	Scanners only for Microarrays .....	85
	Market Growth .....	85
	Prices and Volumes.....	85
TABLE 14	<i>MICROARRAY SCANNERS: SALES VOLUME AND UNIT PRICES, THROUGH 2007</i> .....	86
TABLE 15	<i>THE MARKET FOR MICROARRAY SCANNERS, THROUGH 2007 (\$ MILLIONS)</i> .....	86
	Geographic Markets.....	86
	Leaders and Market Shares .....	87
	Data Analysis and Measurement .....	87
	The Growing Market for Non-Array Gene Expression .....	87
TABLE 16	<i>THE MARKET FOR NONARRAY-BASED GENE EXPRESSION, THROUGH 2007 (\$ MILLIONS)</i> .....	88
	MODEL ORGANISMS.....	88
TABLE 17	<i>CHARACTERISTICS OF SELECTED MODEL ORGANISMS</i> .....	89
	Reverse Genetics.....	89
	Forward Genetics.....	89
	Yeast.....	90
	Fruit Flies .....	90
	Nematode Worms .....	90
	Zebrafish .....	91
	Knockout Mice .....	91
	Mice as a Valued Model Organism.....	92
	Drawbacks to Model Organism Technology .....	92
	Leading Competitors .....	92
	Deltagen .....	92
	Develogen .....	93
	Diabetes .....	93
	Liver Diseases .....	93
	Obesity .....	93
	Exelixis .....	94
	Comparative Genomics Approach .....	94

Lexicon Genetics .....	95
The Market for Model Organisms.....	95
<i>TABLE 18 THE MARKET FOR MODEL ORGANISMS, THROUGH 2007 (\$</i>	
<i>MILLIONS)</i> .....	95
SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) .....	95
SNPs: One of the Fastest Growing Areas of Genomics	
Research .....	96
Bi-Allelic.....	96
Correlating SNPs with Disease and Drug Response .....	97
Polymorphism Analysis Microarrays.....	97
Three Ways for Optimizing Drug Discovery and	
Development .....	98
SNPs in Drug Target Validation.....	98
Haplotypes .....	99
Using SNPs to Understand Drug Efficacy .....	99
Leading Competitors .....	99
SNP Scoring.....	100
Leading Competitors .....	100
Orchid.....	100
HIGH-THROUGHPUT SCREENING .....	101
LEADING COMPETITORS.....	101
Caliper.....	101
Galapagos.....	102
Nascacell .....	102
THE MARKET FOR HIGH-THROUGHPUT SCREENING.....	103
<i>TABLE 19 THE MARKET FOR HIGH-THROUGHPUT SCREENING, THROUGH</i>	
<i>2007 (\$ MILLIONS)</i> .....	103
<i>FIGURE 7 THE MARKET FOR HIGH-THROUGHPUT SCREENING, 2001-2007 (\$</i>	
<i>MILLIONS)</i> .....	103
PHARMACOGENOMICS.....	103
PHARMACOGENOMICS IN DRUG DISCOVERY AND	
DEVELOPMENT .....	104
Three Areas of Benefit.....	104
APPLICATIONS OF PHARMACOGENOMICS.....	105
Selecting the Patient Subpopulation .....	105
Four Subsets of Trial Participants.....	106
Next, a Diagnostic Test .....	106
Avoiding Adverse Effects.....	106
Resurrecting Failed Drugs .....	107
Developing Diagnostics .....	107
THE MARKET FOR PHARMACOGENOMICS .....	107
<i>TABLE 20 THE MARKET FOR PHARMACOGENOMICS, THROUGH 2007 (\$</i>	
<i>MILLIONS)</i> .....	108
<i>FIGURE 8 THE MARKET FOR PHARMACOGENOMICS, THROUGH 2007 (\$</i>	
<i>MILLIONS)</i> .....	108
COMPETITORS IN PHARMACOGENOMICS .....	108



Orchid Biosystems .....	108
Variagenics .....	109
PROTEOMICS .....	109
WHAT IS PROTEOMICS? .....	110
Proteins: the Business End of Biological Information .....	110
FROM GENOMICS TO PROTEOMICS TO DRUG DISCOVERY ....	111
Cell Proteins Vary with Age, Metabolism, and	
Environments .....	111
USING BIOINFORMATICS TO STUDY PROTEINS.....	112
TABLE 21 SELECTED COMMERCIAL PROTEOMICS DATABASES.....	113
CHALLENGES IN PROTEOMICS .....	114
PROTEIN EXPRESSION .....	115
High-Level Mammalian Protein Production .....	115
PROTEIN FUNCTION .....	115
High-Throughput Mass Spectrometry Method .....	116
LEADING METHODS USED IN PROTEOMICS .....	117
Phage Display .....	117
Yeast Two-Hybrid System.....	117
Hybrigenics .....	118
Myriad Genetics.....	118
Mass Spectrometry .....	118
Identifying Indirect Interactions.....	119
Myriad Genetics.....	119
Matrix Assisted Laser Desorption Ionization (MALDI)	
and Electrospray Ionization (ESI) .....	119
Peptide Mass Fingerprint.....	119
NEW TECHNOLOGIES IN THE ANALYSIS OF PROTEINS	
AND PROTEIN NETWORKS .....	120
TABLE 22 EMERGING TECHNOLOGIES IN THE FIELD OF PROTEOMICS.....	121
Solution-Phase Proteomics.....	121
Protein Interaction Mapping.....	122
Genomic BIOprinting .....	122
Gene Expression Cascades .....	122
Protein Microarrays.....	123
Basically, a Protein Chip is a Slide .....	123
Uses for Protein Chips.....	124
Applications to Drug Discovery and Development .....	125
Varieties of Protein Biochips .....	126
Obstacles to Development .....	126
Leading Companies in Protein Chips .....	127
TABLE 23 DEVELOPERS OF PROTEIN CHIPS .....	127
TABLE 23 CONTINUED).....	128
Celera/SomaLogic.....	129
CIPHERGEN Biosystems .....	129
GLAUCUS Proteomics/Medarex/Genmab A/B.....	130

Large Scale Biology/Biosite Diagnostics .....	130
Phylos .....	130
Zyomyx .....	131
Tests of the Zyomyx Protein Profiling	
Biochip .....	131
The Market for Protein Chips .....	132
TABLE 24 THE MARKET FOR PROTEIN MICROARRAYS, THROUGH 2007 (\$	
MILLIONS) .....	133
FIGURE 9 THE MARKET FOR PROTEIN MICROARRAYS, THROUGH 2007 (\$	
MILLIONS) .....	133
The Market for Bioinformatics Used in Proteomics .....	133
TABLE 25 PROJECTIONS FOR PROTEOMICS-RELATED BIOINFORMATICS	
EXPENDITURES, THROUGH 2007 (\$ MILLIONS).....	134
FIGURE 10 PROJECTIONS FOR PROTEOMICS-RELATED BIOINFORMATICS	
EXPENDITURES, 2001-2007 (\$ MILLIONS) .....	134
Obstacles to Widespread Commercialization of	
Protein Chips .....	134
Fluorescent Polyacrylamide Gel Electrophoresis (PAGE)	
and Digital Imaging and Analysis.....	135
Leading Competitors .....	136
THE MARKET FOR PROTEOMICS.....	136
TABLE 26 THE MARKET FOR PROTEOMICS, THROUGH 2007 (\$ MILLIONS).....	136
FIGURE 11 THE MARKET FOR PROTEOMICS, 2001-2007 (\$ MILLIONS).....	136
GENOMICS-BASED DRUGS IN CLINICAL TRIALS .....	137
OTHER INNOVATIVE GENOMICS TECHNOLOGIES USED IN	
DRUG TARGET VALIDATION.....	137
AFFINITY PROBES .....	137
ANTIBODIES.....	138
Chromophore-Assisted Laser Inactivation (CALI).....	138
ANTISENSE.....	139
Ribozymes .....	140
Leading Competitors .....	140
atugen AG .....	140
Genetrove .....	141
Sequitur.....	142
SomaGenics.....	142
Litigation between Isis Pharmaceuticals and	
Sequitur .....	143
COMBINATORIAL CHEMISTRY.....	144
PROMISCUITY STUDIES .....	144
RNA INTERFERENCE .....	145
SYSTEMS BIOLOGY.....	146
INDUSTRY .....	147
WHAT GENOMICS MEANS FOR THE PHARMACEUTICAL	
INDUSTRY .....	147

THE EMERGENCE OF CHRONIC AND MORE COMPLEX DISEASES.....	147
THE NEED FOR LESS EXPENSIVE RESEARCH AND DEVELOPMENT TECHNOLOGIES.....	147
A WHOLE NEW BALL GAME.....	148
BIOLOGY-BASED MEDICINE.....	148
GENOMICS-BASED DRUG TARGET VALIDATION DECREASES DISCOVERY AND DEVELOPMENT TIMELINES .....	149
GENOMICS-BASED DRUG TARGET VALIDATION CAN ENHANCE CLINICAL TRIAL SUCCESS RATES.....	149
GENOMICS CAN EXTEND THE PATENT LIFE OF A DRUG .....	150
THE MOVE FROM TECHNOLOGY PLATFORM-BASED GENOMICS COMPANIES TO FULLY INTEGRATED DRUG DEVELOPMENT FIRMS .....	150
MERGERS AND ACQUISITIONS AMONG GENOMICS-BASED COMPANIES.....	150
<i>TABLE 27 ACQUISITIONS BY GENOMICS COMPANIES.....</i>	<i>151</i>
EVERYBODY'S ON THE BANDWAGON .....	151
Technology Platform Companies .....	151
Drug Development Companies .....	152
Suppliers .....	152
Industrial Products.....	152
COMPETITORS IN APPLIED GENOMICS.....	152
<i>TABLE 28 COMPETITORS IN APPLIED GENOMICS, BY MARKET SECTOR.....</i>	<i>153</i>
<i>TABLE 28 (CONTINUED).....</i>	<i>154</i>
A PROFITABILITY SNAPSHOT—	
TECHNOLOGY/PRODUCT/SERVICE PROVIDERS VERSUS DRUG DEVELOPMENT/MARKETER COMPANIES .....	154
<i>TABLE 29 REVENUES AND NET INCOME/LOSS FOR PRODUCT/SERVICE GENOMICS COMPANIES VERSUS COMPANIES TRANSITIONING TO DRUG DEVELOPERS/MARKETERS, 2001-2006 (\$ MILLIONS).....</i>	<i>155</i>
REGULATORY ISSUES.....	156
FDA APPROVAL TIMES FOR GENOMICS-BASED DRUGS.....	156
PATENTS.....	156
WHAT IS PATENTABLE?.....	156
EXPRESSED SEQUENCE TAGS, PURIFIED GENES AND SINGLE NUCLEOTIDE POLYMORPHISMS .....	157
DISEASE-RELATED ALLELES .....	158
FULL-LENGTH GENES AND GENE FRAGMENTS .....	158
SECRETED PROTEIN THERAPEUTICS.....	158
DIAGNOSTIC AND PHARMACOGENOMIC MARKERS .....	158
THE MOST IMPORTANT PATENTS.....	159
Leading Companies by Full-Sequence Gene Patents .....	159

<i>TABLE 30 LEADING COMPANIES BY FILED PATENT APPLICATIONS ON FULL-LENGTH GENES</i> .....	159
OVERSEAS PATENTS .....	159
COMPANIES DEVELOPING VIRTUAL DISEASES AND VIRTUAL CLINICAL TRIAL TECHNOLOGIES .....	160
ENTELOS .....	160
PHARSIGHT .....	161
COMPANY PROFILES .....	162
TECHNOLOGY PLATFORM-BASED COMPANIES .....	162
AFFYMETRIX, INC. ....	162
Business Overview .....	162
Financial Information .....	162
Products .....	162
Products (Continued) .....	163
Products (Continued) .....	164
Corporate Strategy .....	165
Corporate Strategy (Continued) .....	166
APPLIED BIOSYSTEMS .....	167
Business Overview .....	167
Financial Information .....	168
Products .....	168
<i>TABLE 31 APPLIED BIOSYSTEMS' DNA SEQUENCER PRODUCT LINE</i> .....	169
Corporate Strategy .....	170
CYTOGENIX, INC. ....	171
Company Information .....	171
Financial Information .....	172
Corporate Strategy .....	173
GENE LOGIC INC. ....	174
Business Overview .....	174
Financial Information .....	174
Leading Products .....	175
Corporate Strategy .....	176
HYSEQ PHARMACEUTICALS .....	177
Business Overview .....	177
Financial Information .....	177
Leading Products .....	178
Corporate Strategy .....	178
Corporate Strategy (Continued) .....	179
Corporate Strategy (Continued) .....	180
ORCHID BIOSCIENCES .....	181
Business Overview .....	181
Financial Information .....	182
Products .....	182
Corporate Strategy .....	183

COMPANIES TRANSITIONING TO BECOME DRUG DEVELOPERS AND MARKETERS .....	184
CELERA GENOMICS CORPORATION .....	185
Business Overview .....	185
Financial Information .....	185
Products .....	186
Corporate Strategy .....	187
Corporate Strategy (Continued).....	188
CURAGEN CORPORATION .....	189
Business Overview .....	189
Financial Information .....	189
Leading Products.....	189
Leading Products (Continued).....	190
Corporate Strategy .....	191
Corporate Strategy (Continued).....	192
DELTAGEN, INC. ....	193
Business Overview .....	193
Financial Information .....	193
Products .....	193
Products (Continued).....	194
Corporate Strategy .....	195
EXELIXIS, INC. ....	196
Business Overview .....	196
Financial Information .....	196
Products .....	196
Products (Continued).....	197
Corporate Strategy .....	198
<i>TABLE 32 EXELIXIS' PARTNERSHIPS</i> .....	198
Corporate Strategy (Continued).....	199
HUMAN GENOME SCIENCES, INC. ....	200
Business Overview .....	200
Financial Information .....	201
Leading Products.....	201
<i>TABLE 33 HUMAN GENOME SCIENCES' PRODUCT PIPELINE</i> .....	201
Corporate Strategy .....	202
Corporate Strategy (Continued).....	203
Corporate Strategy (Continued).....	204
INCYTE GENOMICS, INC. ....	205
Business Overview .....	205
Financial Information .....	205
Leading Products.....	206
Corporate Strategy .....	207
Corporate Strategy (Continued).....	208
LEXICON GENETICS .....	209
Business Overview .....	209

Financial Information .....	209
Products .....	209
Corporate Strategy .....	210
Corporate Strategy (Continued).....	211
MILLENNIUM PHARMACEUTICALS, INC.....	212
Business Overview .....	212
Financial Information .....	212
Leading Products .....	213
Corporate Strategy .....	214
Corporate Strategy (Continued).....	215
MYRIAD GENETICS, INC. ....	216
Business Overview .....	216
Financial Information .....	216
Leading Products .....	216
Diagnostics.....	216
Diagnostics (Continued) .....	217
Therapeutics .....	218
Corporate Strategy .....	219
Corporate Strategy (Continued).....	220
NANOGEN, INC. ....	221
Business Overview .....	221
Financial Information .....	222
Leading Products .....	222
Leading Products (Continued).....	223
Corporate Strategy .....	224
Corporate Strategy (Continued).....	225
SEQUENOM, INC.....	226
Business Overview .....	226
Financial Information .....	226
Leading Products .....	227
Corporate Strategy .....	228
Corporate Strategy (Continued).....	229
Corporate Strategy (Continued).....	230
APPENDIX: GLOSSARY OF ACRONYMS.....	231
APPENDIX: GLOSSARY OF ACRONYMS (CONTINUED) .....	232